Compare Eli Lilly And Co (LLY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Natera Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,231.35 (market cap $1.08T), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Eli Lilly And Co is far larger — about 18.9× Natera Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.57% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Natera Inc. Common Stock for 0 Days on average.
| LLY | NTRA | |
|---|---|---|
Market Cap | $1.08T | $57.03B |
Volume | 2,520,401 | 1,131,157 |
Sector | Health | Health |
52-Week High | $1.28K | $425.64 |
52-Week Low | $799.57 | $179.42 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $56.18B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
